诺和诺德宣布，其创新长效生长激素诺泽优®（通用名：帕西生长激素注射液）已于2026年9月8日获得中国国家药品监督管理局批准，新增用于治疗努南综合征（NS）相关生长迟缓的2.5岁及以上儿童患者,特发性身材矮小（ISS）的2.5岁及以上儿童患者,出生时为小于胎龄儿（SGA）且2岁时无法追赶生长的身材矮小的2.5岁及以上儿童患者。 （文章来源：第一财经）
Source Link诺和诺德宣布，其创新长效生长激素诺泽优®（通用名：帕西生长激素注射液）已于2026年9月8日获得中国国家药品监督管理局批准，新增用于治疗努南综合征（NS）相关生长迟缓的2.5岁及以上儿童患者,特发性身材矮小（ISS）的2.5岁及以上儿童患者,出生时为小于胎龄儿（SGA）且2岁时无法追赶生长的身材矮小的2.5岁及以上儿童患者。 （文章来源：第一财经）
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.